These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1033 related articles for article (PubMed ID: 19362586)

  • 1. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y; Calvert H
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
    Drew Y; Plummer R
    Drug Resist Updat; 2009 Dec; 12(6):153-6. PubMed ID: 19939726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
    Drew Y; Plummer R
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):67-71. PubMed ID: 19934756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase: a new therapeutic target?
    Gerö D; Szabó C
    Curr Opin Anaesthesiol; 2008 Apr; 21(2):111-21. PubMed ID: 18443476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    Gaziev AI
    Radiats Biol Radioecol; 2014; 54(3):229-40. PubMed ID: 25764827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Tentori L; Portarena I; Graziani G
    Pharmacol Res; 2002 Feb; 45(2):73-85. PubMed ID: 11846617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S; Thomas HD; Mitchell J; Curtin NJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
    Virág L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
    Curtin NJ; Szabo C
    Mol Aspects Med; 2013 Dec; 34(6):1217-56. PubMed ID: 23370117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
    Erdélyi K; Bakondi E; Gergely P; Szabó C; Virág L
    Cell Mol Life Sci; 2005 Apr; 62(7-8):751-9. PubMed ID: 15868400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions.
    Beneke S; Diefenbach J; Bürkle A
    Int J Cancer; 2004 Oct; 111(6):813-8. PubMed ID: 15300792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.